← Leaderboards
Jack H Nunberg
University Of Montana
$8,592,049
Attributed
$8,707,290
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $918.9K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,707,290 · 14
By mechanism
R01$3,908,930 · 3
R21$1,896,394 · 5
U54$1,823,351 · 1
R15$426,801 · 1
R56$373,750 · 1
R03$140,000 · 1
Top collaborators
- Alex S Evers1 shared
Others in their field
Top investigators on “Glycoproteins”
- Dennis R. Burton · Scripps Research Institute$211,788,189
- Joseph G Sodroski · University Of Pennsylvania$47,423,604
- Kartik Chandran · Albert Einstein College Of Medicine$41,665,810
- Erica Ollmann Saphire · Scripps Research Institute$32,718,575
- Robert F Garry · Scripps Research Institute, The$32,430,244
- James E Crowe · Vanderbilt University Medical Center$32,099,289
Research focus
GlycoproteinsRodentMembrane FusionVirusArenavirusViral Hemorrhagic FeversJunin VirusMolecularPeptide Signal SequencesDesignComplexStructureMediatingCellsSmall MoleculeVaccinesInfectionMembrane Fusion ActivityInhibitor/AntagonistBiodefenseMembraneGeneticArenavirus InfectionsReceptor Binding
Grant awards (34)
Rational design of a safe recombinant Candid#1 vaccine$363,907
R01 · FY2024 · AI · contact PI
Rational design of a safe recombinant Candid#1 vaccine$363,779
R01 · FY2023 · AI · contact PI
Rational design of a safe recombinant Candid#1 vaccine$363,627
R01 · FY2022 · AI · contact PI
Rational design of a safe recombinant Candid#1 vaccine$378,975
R01 · FY2021 · AI · contact PI
Design and development of a safe recombinant Candid#1 vaccine$373,750
R56 · FY2019 · AI · contact PI
CryoEM structural analysis of Lassa virus GPC$164,003
R21 · FY2018 · AI · contact PI
CryoEM structural analysis of Lassa virus GPC$211,769
R21 · FY2017 · AI · contact PI
Intersubunit crosstalk in the tripartite arenavirus envelope glycoprotein$426,801
R15 · FY2016 · AI · contact PI
Integrated Phosphor and Fluorescence Imager (Typhoon FLA9500)$138,064
S10 · FY2016 · OD · contact PI
Characterization of the pH-sensing interface of the arenavirus envelope glycoprotein GPC$230,483
R21 · FY2015 · AI · contact PI
Arenavirus entry and it's inhibition$360,805
U54 · FY2013 · AI · contact PI
Molecular determinants of host-cell interactions required for arenavirus replicat$166,263
R21 · FY2013 · AI · contact PI
Arenavirus entry and it's inhibition$394,328
U54 · FY2012 · AI · contact PI
Structure-function studies of the tripartite Junin arenavirus GP-C$312,039
R01 · FY2012 · AI · contact PI
Molecular determinants of host-cell interactions required for arenavirus replicat$212,563
R21 · FY2012 · AI · contact PI
Arenavirus entry and it's inhibition$352,371
U54 · FY2011 · AI · contact PI
Structure-function studies of the tripartite Junin arenavirus GP-C$312,039
R01 · FY2011 · AI · contact PI
Arenavirus entry and it's inhibition$394,184
U54 · FY2010 · AI · contact PI
Structure-function studies of the tripartite Junin arenavirus GP-C$383,060
R01 · FY2010 · AI · contact PI
Arenavirus entry and it's inhibition$321,663
U54 · FY2009 · AI · contact PI
Structure-function studies of the tripartite Junin arenavirus GP-C$318,375
R01 · FY2009 · AI · contact PI
Structure-function studies of the tripartite Junin arenavirus GP-C$318,375
R01 · FY2008 · AI · contact PI
Structure-function of Junin virus envelope glycoproteins$246,313
R21 · FY2005 · AI
Structure-function of Junin virus envelope glycoproteins$245,000
R21 · FY2004 · AI
Genetic analysis of the HIV gp120-gp41 interface$210,000
R21 · FY2004 · AI
Chimeric hepatitis C vaccine vector$70,000
R03 · FY2004 · AI
Genetic analysis of the HIV gp120-gp41 interface$210,000
R21 · FY2003 · AI
Chimeric hepatitis C vaccine vector$70,000
R03 · FY2003 · AI
FUSION COMPETENT HIV VACCINE IMMUNOGENS$272,786
R01 · FY2002 · AI
ACCESS TO GCG WISCONSIN SEQUENCE ANALYSIS PACKAGE FOR HIV RES &BIOTECH CENTER$0
P41 · FY2002 · RR
ACCESS TO GCG WISCONSIN SEQUENCE ANALYSIS PACKAGE FOR HIV RES &BIOTECH CENTER$0
P41 · FY2002 · RR
FUSION COMPETENT HIV VACCINE IMMUNOGENS$264,841
R01 · FY2001 · AI
ACCESS TO GCG WISCONSIN SEQUENCE ANALYSIS PACKAGE FOR HIV RES &BIOTECH CENTER$0
P41 · FY2001 · RR
FUSION COMPETENT HIV VACCINE IMMUNOGENS$257,127
R01 · FY2000 · AI